학술논문
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Document Type
Article
Author
Schadendorf, Dirk; Hauschild, Axel; Santinami, Mario; Atkinson, Victoria; Mandalà, Mario; Chiarion-Sileni, Vanna; Larkin, James; Nyakas, Marta; Dutriaux, Caroline; Haydon, Andrew; Robert, Caroline; Mortier, Laurent; Lesimple, Thierry; Plummer, Ruth; Schachter, Jacob; Dasgupta, Kohinoor; Manson, Stephanie; Koruth, Roy; Mookerjee, Bijoyesh; Kefford, Richard; Dummer, Reinhard; Kirkwood, John M; Long, Georgina V
Source
In The Lancet Oncology May 2019 20(5):701-710
Subject
Language
ISSN
1470-2045